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Neonatal bloodstream infections in a
Ghanaian Tertiary Hospital: Are the current
antibiotic recommendations adequate?
Appiah-Korang Labi1, Noah Obeng-Nkrumah2*, Stephanie Bjerrum3, Christabel Enweronu-Laryea4
and Mercy Jemima Newman5
Abstract
Background: Diagnosis of bloodstream infections (BSI) in neonates is usually difficult due to minimal symptoms at
presentation; thus early empirical therapy guided by local antibiotic susceptibility profile is necessary to improve
therapeutic outcomes.
Methods: A review of neonatal blood cultures submitted to the microbiology department of the Korle-Bu Teaching
Hospital was conducted from January 2010 through December 2013. We assessed the prevalence of bacteria and
fungi involved in BSI and the susceptibility coverage of recommended empiric antibiotics by Ghana Standard
Treatment guidelines and the WHO recommendations for managing neonatal sepsis. The national and WHO
treatment guidelines recommend either ampicillin plus gentamicin or ampicillin plus cefotaxime for empiric
treatment of neonatal BSI. The WHO recommendations also include cloxacillin plus gentamicin. We described
the resistance profile over a 28-day neonatal period using multivariable logistic regression analysis with linear or
restricted cubic splines.
Results: A total of 8,025 neonatal blood culture reports were reviewed over the four-year period. Total blood
culture positivity was 21.9 %. Gram positive organisms accounted for most positive cultures, with coagulase
negative staphylococci (CoNS) being the most frequently isolated pathogen in early onset infections (EOS) (59.1 %)
and late onset infections (LOS) (52.8 %). Susceptibility coverage of early onset bacterial isolates were 20.7 % to
ampicillin plus cefotaxime, 32.2 % to the combination of ampicillin and gentamicin, and 71.7 % to cloxacillin plus
gentamicin. For LOS, coverage was 24.6 % to ampicillin plus cefotaxime, 36.2 % to the combination ampicillin and
gentamicin and 63.6 % to cloxacillin plus gentamicin. Cloxacillin plus gentamicin remained the most active regimen
for EOS and LOS after exclusion of BSI caused by CoNS. For this regimen, the adjusted odds of resistance decreased
between 12-34 % per day from birth to day 3 followed by the slowest rate of resistance increase, compared to the
other antibiotic regimen, thereafter until day 28. The trend in resistance remained generally unchanged after
excluding data from CoNS. Multidrug resistant isolates were significantly (p-value <0.001) higher in LOS (62.4 %,
n = 555/886) than in EOS (37.3 %, n = 331/886).
Conclusions: There is low antibiotic susceptibility coverage for organisms causing neonatal bloodstream infections
in Korle-Bu Teaching Hospital when the current national and WHO recommended empiric antibiotics were
assessed. A continuous surveillance of neonatal BSI is required to guide hospital and national antibiotic treatment
guidelines for neonatal sepsis.
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Background
The neonatal age represents a critical period in the life of
an infant. The immature state of their immune system
predisposes them to infections [1]. Of these, bloodstream
infections (BSI) are the most important because of their
association with increased cost, morbidity and mortality
[1–3]. In Africa, neonatal bloodstream infection rates are
estimated to be 20 per 1000 live births’; mainly ascribed to
poor intra-partum and postnatal practices [4, 5]. Neonatal
bloodstream infections may be of early or late onset. Early
onset neonatal BSI (i.e. infections occurring within first
48 h of life) [3] is mostly due to vertical transmission from
maternal flora during the perinatal period [6]. Group B
Streptococcus is the typical organism isolated during this
period in developed countries although other bacteria do
play a role [3]. Late onset neonatal BSI (infections occur-
ring past 48 h after birth) [3] are caused by organisms
from the hospital or home environment [4, 6]. Commonly
associated pathogens are Staphylococcus species and
Gram negative bacteria mainly Enterobacteriaceae [1–3].
In neonates early signs and symptoms of BSI are min-
imal, making it difficult to diagnose [1, 3]. This means
empirical antibiotic management of suspected BSI must
be started immediately to reduce associated morbidity
and mortality. The antibiotic of choice must cover com-
monly isolated organisms, and must take into account
their known local antibiotic susceptibility patterns. How-
ever in developing countries, antimicrobial therapy is
usually based on international recommendations without
adaptation to local susceptibility patterns; although it
has been shown that evidence based treatment improves
treatment outcomes [7]. Rising incidence of multi-drug
resistant bacteria worldwide [8], and the variability of
antibiotic susceptibility patterns by location, means that
local antibiotic susceptibility profiles are invaluable to ef-
fective empiric antibiotic therapy.
Very few published data on neonatal bloodstream
infections exist in Ghana and the West African sub-
region. A study conducted among neonates in a major
teaching Hospital in Ghana, described decreasing sus-
ceptibility of Gram negative organisms to aminoglyco-
sides and cephalosporins [5]. The evolving nature of
antibiotic resistance means that there is the need to
regularly update antibiotic susceptibility data to guide
empiric therapy. The aim of this study was to describe
bacterial and fungal isolates from neonatal blood cul-
tures processed at the Microbiology Department of the
Korle-Bu Teaching Hospital (KBTH) over a four year
period (2010–2013); with emphasis on antibiotic sus-
ceptibility patterns, multi-drug resistant isolates and
coverage of antibiotics suggested by the current na-
tional standard treatment guidelines [9] and the World
Health Organisation (WHO) [10] for treating neonatal
sepsis. This information may contribute to improved
management of neonatal sepsis and the development of
local policies based on local epidemiological information.
Methods
Study design and setting
We conducted a retrospective review of neonatal blood
cultures over a 4-year period from January 2010 through
December 2013. Given that the current definition of
neonatal BSI incorporate time thresholds that delimit in-
fections between 0 and 28 days after birth, only blood
cultures with information on age of patients at time of
sampling were considered for review and analyses. Blood
culture reports of newborn infants were collated from
the bacteriology unit of the Microbiology Department of
KBTH, which processes over 40,000 clinical cultures
annually. We included blood culture results of neonates
primarily receiving healthcare at the KBTH (n = 7,594)
or secondarily referred to the laboratory from other
health facilities for microbiological investigations (n =
431). Blood cultures from KBTH were from the Babies
Unit and neonatal intensive care units of the Depart-
ment of Child Health. The Department of Child Health
has a 55-bed neonatal intensive care unit; and a 40-bed
Babies Unit for neonatal cases referred to KBTH [11].
The hospital annually records about 11,000 live births;
and provides referral healthcare services to an estimated
population of 24 million Ghanaians [11].
Laboratory procedures
Over the period under review the laboratory performed
8,025 neonatal blood cultures. For neonatal patients,
the guideline is to inject between 1-3 mL of blood directly
into Paediatric Bactec® culture vials (Becton Dickinson,
USA). These are then submitted for laboratory diagnosis.
Cultures are processed with the BACTEC 9240 blood
culture system (Becton Dickinson, NJ, USA) according
to manufacturer’s instructions. Subcultures are typically
made on to blood, chocolate, MacConkey and Saboraund
agars; and incubated aerobically at 37 °C for 20 h. Identifi-
cation of bacterial isolates was performed by Gram-stain
microscopy and with routine biochemical methods.
Bacteria speciation was done with the BBL Crystal
identification system (Becton Dickinson, NJ, USA).
Antibiotic susceptibility testing was performed using
the Kirby Bauer Disc diffusion method in accordance to
Clinical and Laboratory Standards Institute guidelines.
Positive blood cultures for yeast and non-yeast fungi
were identified on the basis of macromorphology (includ-
ing estimation of radial growth on selected media) and
microscopic examinations of sexual reproduction, coni-
diogenesis, and hyphal branching. Routinely at the labora-
tory, positive blood cultures are evaluated to determine
whether they represent true bacteraemia, fungaemia, or
contamination - they are each reviewed by the Clinical
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Microbiologist for decisions on the significance of the or-
ganism and the appropriate antibiotic susceptibility data
to report. The Clinical Microbiologists have access to pa-
tients’ clinical information.
Review and analysis
Study data were collected by physician-assisted review of
laboratory records. Information extracted included gen-
der, age and year of infection, the isolated organism and
antibiotic susceptibility data. For purposes of this study,
positive blood cultures were those with bacteria or fungi
(i) recovered and for which antibiotic susceptibility tests
were performed (if isolates were bacteria); and (ii) identi-
fied as the first isolate per patients within the study
period. If more than one organism was isolated from a
single culture this was classified as a poly-microbial
infection. Certain organisms, including Micrococcus spe-
cies, Bacillus species, and diptheroids were classified as
contaminants. Coagulase negative Staphylococci (CoNS)
because of their possible role as pathogens in this age
group were included in the overall data for analysis except
where specified in the laboratory records as contaminants
with no antimicrobial susceptibility data. Neonatal BSI
was defined by at least one set of positive blood culture
for bacteria or fungi in an infant 28 days old or younger.
Bloodstream infections were sub-classified into early onset
(EOS) if it occurred <48 h and late onset (LOS) if it oc-
curred 2–28 days after birth. Positive cultures were further
categorized into Gram-positive bacteria, Gram-negative
organisms, and fungi.
Antimicrobial susceptibility
Empirical choice of antibiotics at the KBTH is varied
and may involve ampicillin, cloxacillin, gentamicin, ami-
kacin, or ceftotaxime in various combinations. However
the national and WHO treatment guidelines recom-
mend either ampicillin plus gentamicin or ampicillin
plus cefotaxime for empiric treatment of neonatal BSI
[9]. The WHO recommendations also include cloxacil-
lin plus gentamicin [10]. Susceptibility of bacterial iso-
lates to the recommended regimen was evaluated based
on reported antibiogram. Isolates were described as
susceptible to the combination regimens if they were
reported susceptible in vitro to either one or both of
the antibiotics recommended. Susceptibility profiles of
isolates to different treatment regimens were repeated
after excluding BSI with CoNS. We assessed the occur-
rence of multidrug resistant bacteria between early and
late onset infections, focusing on six epidemiological bac-
terial pathogens: vancomycin resistant Enterococcocus spe-
cies (VRE) [based on in vitro susceptibility to vancomycin
disk (30ug)], methicillin resistant Staphylococcus aureus
(MRSA) [based on in vitro susceptibility to cefoxitin disk
(30ug)], penicillin resistant streptococci (PRS) [based on
in vitro susceptibility to ampicillin disk (10ug)], ceph-
alosporin resistant enterobacteria (Ceph-R Ent) [based
on in vitro susceptibility to cefotaxime disk (30ug)],
multi-drug resistant Pseudomonas species (MDR Ps.)
and multi-drug resistant Acinetobacter species (MDR
Act). Multidrug resistant (MDR) phenotype was defined
according to the international standard definitions for
acquired resistance, and relative to the panel of antibiotics
tested for each isolate, as in vitro non-susceptibility to ≥1
agent in ≥3 antimicrobial categories: penicillins, cepha-
losporins, beta-lactamase inhibitor combinations, fluor-
oquinolones, aminoglycosides, chloramphenicol, folate
pathway inhibitors, tetracyclines, macrolides and glyco-
peptides [12].
Statistics
Study data was captured into Microsoft Excel, and
exported into Statistical Package for Social Sciences
(SPSS, Version 20.0) for editing and statistical analyses.
Where appropriate, data were compared between four
consecutive study periods (2010 through 2013) so that
trends could be ascertained. Comparisons between cat-
egorical data were conducted with Fisher’s exact test or
Chi-square with Marascuilo’s post hoc tests for multiple
comparisons. Changes in incidence over time were
analyzed by Chi-square test for trend. Continuous data
were compared using students’ t-test with analyses of
variance (ANOVA) for multiple comparisons. A multi-
variable logistic regression with linear or restricted
cubic splines was used to model the association be-
tween the proportion of resistant bacteria causing BSI
and the age of neonates at the time of blood culture
sampling. The number and placement of spline knots
was based on a previously published method by Blackburn
et al., 2014 [13], using ‘mkspline functions’ created in Stata
version 12 (StataCorp., USA). Each linear spline incorpo-
rated one, two, three or four knots. Restricted cubic
splines included four knots. Logistic regression models
with the best fit were chosen based on the Akaike’s Infor-
mation Criterion (AIC). Models with least AIC values
were preferred. Organisms, year of infections and patients’
gender were included in the models as cross-factor ran-
dom effects, continuous and binary variables, respectively.
The likelihood ratio test was used to determine the statis-
tical significance for outcomes in the regression models.
Point estimates of statistical significance were indicated
with 2-tailed p-values <0.05. Logistic regression analysis
were repeated after excluding BSI with CoNS.
Results
From January 2010 through December 2013, we reviewed
8025 blood culture reports of neonates. Contaminants
accounted for 3.6 % (n = 294); and these were more
prevalent (p-value = 0.001) in newborns <48 h old (17.2 %;
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n = 151/875) than in neonates 2–28 days old (12.1 %; n =
143/1182). Blood culture positivity was 21.9 % (n = 1763/
8025), and remained significantly higher among neonates
receiving care at KBTH (22.5 %, n = 1712/7594) compared
to those referred to the laboratory from elsewhere (11.8 %,
n = 51/431). In the proceeding analysis however, we have
disregarded comparing results between the two sources of
blood cultures due to few true positive cultures from the
latter.
Isolates from neonatal BSI
Ranked distributions for reported organisms are presented
in Table 1 for EOS and LOS. The data show a predomin-
ance (p-value <0.001) of LOS (13.0 %, n = 1039/8025) over
EOS (9.0 %, n = 724/8025). Gram-positive organisms
accounted for the majority of BSI and were significantly
(p-value =0.001) more prevalent in EOS (84.2 %, n = 610/
724) compared to LOS (78.1 %, n = 811/1039). Coagulase
negative Staphylococci were the most frequent organ-
ism (EOS: 59.1 % > LOS: 52.8 %; p-value = 0.005),
followed by Staphylococcus aureus (EOS: 10.5 % < LOS:
15.3 %; p-value = 0.003) and Streptococcus species (EOS:
8.1 % > LOS: 5.6 %; p-value = 0.003). For EOS Citrobac-
ter (3.2 %, n = 23/724) and Enterobacter (2.6 %, n = 19/
724) species were the most frequently reported Gram
negative bacteria. Citrobacter species accounted for the
majority of Gram negative bacteria reported in LOS
(4.3 %, n = 44/1039). There was a trend towards in-
creased incidence of CoNS in EOS, from 55.3 % in
2010 to 65.4 % in 2013 (Chi- square for trend analysis,
p-value <0.001). In LOS, we observed a rise in Candida
species from 0 in 2010 to 0.4 % (n = 1/261) in 2011,
0.6 % (n = 2/352) in 2012 and 3.3 % (n = 5/151) in 2013
(Chi- square for trend, p-value <0.001).
Antibiotic susceptibility
Table 2 compares in vitro susceptibility of bacterial
isolates to empiric antimicrobials used for treatment
of neonatal sepsis. In EOS, the susceptibility of all iso-
lates was 20.7 % to ampicillin plus cefotaxime, 32.2 %
to the combination of ampicillin and gentamicin and
71.6 % to cloxacillin plus gentamicin (Chi-square for
trend, p-value <0.001). In Table 3 the antimicrobial
profiles for all bacteria isolated from LOS showed that
susceptibility was 24.6 % to ampicillin plus cefotaxime,
36.2 % to the combination ampicillin and gentamicin and
63.6 % to cloxacillin plus gentamicin (Chi-square for
trend, p-value <0.001). For each treatment regimen, there
was no significant difference in proportion of susceptible
isolates between EOS and LOS. Overall, the combin-
ation of cloxacillin and gentamicin remained the most
active regimen for EOS and LOS even after exclusion of
BSI by CoNS. In EOS, when the analysis excluded data
on CoNS, the susceptibility coverage of cloxacillin/
gentamicin decreased by 7.7 % but this did not achieve
statistical significance (p-value = 0.081). In LOS (Table 3),
susceptibility to cloxacillin plus gentamicin significantly
(p-value = 0.011) reduced from 63.6 % (n = 570/896) to
55.8 % (n = 204/365) after the exclusion of CoNS.
Changes in antibiotic susceptibility over 4-year study
period
Resistance of blood culture isolates to ampicillin/gentamicin
and to cloxacillin/gentamicin remained relatively un-
changed from 2010 through 2013 (Fig. 1). In contrast, we
identified significant increase in resistance to ampicillin/
cefotaxime during the same study period. The yearly trend
in resistance to each regimen remained unchanged after
excluding data on CoNS.
Changes in antibiotic susceptibility over 28-day neonatal
period
The relationship between resistance to each empiric anti-
biotic combinations and neonates’ age was best described
by linear spline functions incorporating one or four age
breakpoints (knots) (Additional file 1: Table S1). After
adjusting for gender, year of infection and bacterial iso-
lates, the odds ratios from multivariable logistic regression
showed evidence of association between resistance and
age for each antibiotic regimen (p-value <0.008 for all
antibiotic combinations) (Additional file 1: Table S2). The
adjusted odds ratios (AOR) can be interpreted as resist-
ance decreasing at varying rates between 12–26 % per day
from birth (day 0) to day 7 for cloxacillin/gentamicin and
ampicillin/cefotaxime, and to day 9 for ampicillin/genta-
micin — followed by increasing resistance levels thereafter
until day 28 (Fig. 2). Ampicillin/gentamicin recorded the
slowest rate in decline of antibiotic resistance. The odds of
resistance fell by 22 % between birth and day 3 followed
by a similar decrease of 22 % per day from days 6–9. The
rate of increase in resistance was slowest for cloxacillin/
gentamicin — the rate increases each day by 24 % from
days 7 through 14 and by 61 % thereafter until 28 days
(Fig. 2). The trends in resistance over 28-day period
remained generally unchanged after excluding data from
CoNS, although increase in adjusted odds of resistance oc-
curred within fewer days after birth (Additional file 1: Table
S2). Resistance decreased between 29-49 % per day from
birth to day 3 for all antibiotic combinations. The decrease
in resistance was greatest for cloxacillin/gentamicin. For
this regimen, the odds of resistance fell by 38 % from birth
to day 1, with a further 11 % decrease in day 2 followed by
increasing resistance thereafter until day 28 (Fig. 2)
Multidrug resistance
Figure 3 compares the occurrence of epidemiologically
important bacterial phenotypes across EOS and LOS. No
carbapenem resistant Enterobacteriaceae was isolated.
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Table 1 Bacteria and fungi isolates from blood cultures of neonates <48 h and 2–28 days old
Organism Total EOS X2 trend
p-value
LOS X2 trend
p-valueNumber of isolates (%) Number of isolates (%)
EOS LOS 2010 2011 2012 2013 2010 2011 2012 2013
Gram negatives 109 (14.9) a 220 (21.7) b 33 (14.0) 16 (11.1) 45 (17.2) 15 (17.8) 0.219 63 (22.9) 41 (15.7) 80 (22.7) 36 (20.5) 0.541
Enterobacteriacea 79 (10.9) 160 (15.3) 28 (11.9) 8 (5.5) 35 (13.4) 8 (9.5) 0.879 45 (16.4) 28 (10.7) 61 (17.3) 26 (17.9) 0.444
Escherichia coli 11 (1.5) 14 (1.3) 2 (0.9) 1 (0.7) 6 (2.2) 2 (2.4) 0.183 5 (1.8) 5 (1.9) 10 (2.8) 4 (2.6) 0.450
Klebsiella species 10 (1.4) 21 (2.0) 3 (1.2) 1 (0.7) 5 (1.9) 1 (1.2) 0.801 5 (1.8) 1 (0.4) 11 (3.1) 4 (2.6) 0.210
Kluyvera species 7 (0.9) 6 (0.6) 5 (2.1) 0 1 (0.4) 1 (1.2) 0.109 1 (0.3) 1 (0.4) 1 (0.2) 3 (2.0) 0.187
Citrobacter species 23 (3.2) 44 (4.3) 7 (2.9) 3 (2.1) 11 (4.2) 2 (2.4) 0.785 16 (5.8) 10 (3.8) 12 (3.4) 6 (4.0) 0.199
Enterobacter species 19 (2.6) 40 (3.9) 6 (2.5) 2 (1.4) 10 (3.8) 1 (1.2) 0.927 14 (5.1) 4 (1.5) 19 (5.4) 3 (2.0) 0.520
Proteus species 5 (0.7) 7 (0.6) 3 (1.2) 1 (0.7) 1 (0.4) 0 0.097 0 2 (0.6) 3 (0.9) 2 (1.3) 0.144
Salmonella species 3 (0.4) 10 (0.9) 1 (0.4) 0 1 (0.4) 1 (1.2) 0.698 3 (1.1) 3 (1.1) 3 (0.9) 1 (0.7) 0.506
Serratia species 1 (0.4) 8 (0.7) 1 (0.4) 0 0 0 0.089 1 (0.3) 2 (0.8) 2 (0.6) 3 (2.0) 0.216
Acinetobacter species 16 (2.2) 43 (4.1) 3 (1.2) 4 (2.7) 4 (1.5) 5 (5.9) 0.131 15 (5.4) 7 (2.6) 13 (3.7) 8 (5.3) 0.740
Pseudomonas species 11 (1.5) 16 (1.5) 2 (0.8) 2 (1.3) 5 (1.9) 2 (2.4) 0.300 3 (1.1) 6 (2.3) 5 (1.4) 2 (1.3) 0.934
Others 3 (0.4) 1 (0.09) 0 2 (1.3) 1 (0.4) 0 0.865 0 0 1 0 0.895
Gram positives 610 (84.2) b 811 (78.0) a 200 (85.1) 127 (88.2) 214 (81.9) 69 (82.1) 0.241 212 (77.1) 219 (83.9) 270 (76.7) 114 (75.5) 0.386
Enterococcus species 43 (5.9) 36 (3.4) 32 (13.7) 3 (2.1) 6 (2.3) 2 (2.4) <0.001 23 (8.4) 5 (1.9) 6 (1.7) 2 (1.3) <0.001
Micrococcus species 1 (0.4) 5 (0.4) 1 (0.4) 0 0 0 0.089 0 1 (0.4) 2 (0.6) 2 (1.3) 0.108
Staphylococcus aureus 76 (10.5) 159 (15.3) 24 (10.2) 20 (13.9) 24 (9.2) 8 (9.5) 0.570 43 (15.6) 51 (19.5) 46 (13) 19 (12.6) 0.142
CoNS 431 (59.5) 549 (52.8) 130 (55.3) 94 (65.2) 152 (58.2) 55 (65.4) <0.001 133 (48.4) 150 (57.5) 195 (55.3) 71 (47.0) 0.844
Streptococcus species 59 (8.1) 58 (5.6) 13 (55.3) 10 32 (12.3) 4 (4.8) 0.162 13 (4.7) 12 (4.6) 21 (6.0) 4 (2.6) 0.698
Streptococcus pneumoniae 3 (0.4) 9 (0.9) 2 (0.8) 0 1 (0.4) 0 0.199 2 (0.6) 1 (0.4) 3 (0.9) 3 (2.0) 0.988
Streptococcus pyogenes 3 (0.4) 9 (0.9) 2 (0.8) 0 1 (0.4) 0 0.199 2 (0.6) 1 (0.4) 3 (0.9) 3 (2.0) 0.295
Streptococcus agalactiae 5 (0.7) 7 (0.6) 2 (0.8) 1 (0.7) 1 (0.4) 1 (1.2) 0.715 1 (0.3) 2 (0.8) 3 (0.9) 1 (1.3) 0.726
Viridans Streptococci 22 (3.0) 16 (1.5) 2 (0.8) 5 (3.5) 13 (4.9) 2 (2.4) 0.073 2 (0.6) 3 (1.1) 7 (1.9) 4 (2.6) 0.102
Other Streptococci 26 (3.6) 17 (1.6) 5 (2.1) 4 (2.8) 16 (6.1) 1 (1.2) 0.288 6 (2.0) 4 (1.5) 5 (1.4) 2 (1.3) 0.378
Streptomyces species 0 4 (0.3) 0 0 0 0 - 0 1 (0.4) 0 3 (2.0) 0.049
Fungi 5 (0.7) a 8 (0.7) a 5 (2.1) 1 (0.7) 2 (0.8) 0 0.053 0 1 (0.4) 2 (0.6) 6 (3.9) <0.001
Aspergillus species 2 (0.2) 0 1 (0.4) 0 1 (0.4) 0 0.480 0 0 0 0 -
Candida albicans 3 (0.4) 8 (0.7) 1 (0.4) 1 (0.06) 1 (0.4) 0 0.467 0 1 (0.4) 2 (0.6) 5 (3.3) <0.001
Total 724 (41.1) 1039 (58.9) 235 144 261 84 275 261 352 151
*Differing superscripts across columns indicate significant difference at p-value <0.05; EOS, early onset infections; LOS, late onset infections; CoNS, coagulase negative staphylococci. Other Gram negatives included
Neisseria species, Stenophromonas species and Moraxella species; Other Streptococci included S. mitis, S. salivarius, S. oralis, S sanguinis group, S bovis, S milleri, S. anginosus, S. constellatus and S. intermedius
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Table 2 Susceptibility (of bacteria from blood cultures taken from neonates less than 48 h old) to antimicrobials used for empiric treatment of neonatal BSI
Organisms Susceptibility
Ampicillin + Gentamicin (A) Ampicillin + Cefotaxime (B) Cloxacillin + Gentamicin (C) Regimen coverage
Number
of isolates
Number Tested (%) Number susceptible (%) Number Tested (%) Number susceptible (%) Number Tested (%) Number susceptible (%)
Gram negatives 109 101 (92.6) 38 (37.6)a 68 (62.4) 32 (47.1)a 75 (68.8) 52 (69.3)b C > B = A; p = 0.001
Enterobacteriacea 79 74 (93.7) 24 (32.4) 55 (69.6) 27 (49.1) 53 (67.1) 37 (69.8)
Acinetobacter species 16 16 (100) 10 (62.5) 13 (81.2) 5 (38.4) 13 (81.2) 8 (61.5)
Pseudomonas species 11 11 (100) 4 (36.4) - - 9 (81.8) 7 (77.7)
Others 3
Gram positives 610 511 (83.8) 159 (31.1)b 356 (58.4) 56 (15.7)a 211 (34.6) 153 (72.5)b C > A > B; p = 0.001
Enterococcus species 43 37 (86.1) 8 (21.6) 37 (86.1) 7 (18.9) - -
Staphylococcus aureus 76 67 (88.2) 34 (50.7) 59 (77.6) 5 (8.5) 69 (90.7) 46 (66.7)
CoNS 431 376 (87.2) 107 (28.5) 226 (52.4) 26 (11.5) 111 (25.7) 93 (83.7) C > A > B; p = 0.001
Streptococcus species 59 31 (52.5) 10 (32.3) 34 (57.6) 18 (30.5) 31 (52.5) 14 (45.2)
Others 1
Total 719 612 (85.1) a197 (32.2)
b 424 (58.9) a 88 (20.7)
a 286 (40.0) a205 (71.7)
c C > A > B; p = 0.001
Total excluding CoNS 288 236 (81.9) a90 (38.1)
a 198 (68.8) b 62 (31.3)
a 175 (60.7) a112 (64.0)
b C > B = A; p = 0.001
Polymicrobial infections 20 19 (95.0) 4 (21)a 18 (90.0) 2 (11.1)a 20 (100.0) 5 (25.0)a C = B = A; p = 0.540
2 organisms 17 16 (94.1) 1 (6.3) 15 (88.2) 1 (6.7) 17 (100) 4 (23.5)
3 organisms 3 3 (100) 3 (100) 3 (100) 1 (33.3) 3 (100) 1 (33.3)
Based on in-vitro susceptibility. Data on isolates with insufficient numbers (n ≤ 5) not shown. For polymicrobial infections, all isolates were susceptible to at least one of the treatment antibiotics
A, Ampicillin plus Gentamicin; B, Ampicillin plus cefotaxime; C, Cloxacillin plus gentamicin; CoNS, Coagulase negative Staphylococcus species. Other Gram-negatives included Neisseria species (n = 1), Stenophromonas
species (n = 1) and Moraxella species (n = 1). Other Gram-positives included Micrococcus species
Differing superscripts across row denotes differences in the proportion of susceptible isolates to antimicrobial regimen. Differences in proportions computed by Chi square with Marascuilo’s Post Hoc Multiple
proportion comparisons at p-value <0.05. Differing subscripts within a column denotes differences in the proportion of susceptible isolates to antimicrobial regimen
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Table 3 Susceptibility (of bacteria from blood cultures taken from neonates between 2 to 28 days) to antimicrobials used for empiric treatment of neonatal septicaemia
Organisms Number of
isolates
Susceptibility
Ampicillin + Gentamicin (A) Ampicillin + Cefotaxime (B) Cloxacillin + Gentamicin (C) Regimen coverage
Number Tested
(%)
Number susceptible
(%)
Number Tested
(%)
Number susceptible
(%)
Number Tested
(%)
Number susceptible
(%)
Gram negatives 220 200 (90.9) 72 (36.0)a 188 (85.4) 92 (48.9)a 173 (0.78) 102 (46.3)b C > B = A; p = 0.001
Enterobacteriacea 160 145 (90.6) 44 (30.3) 149 (93.1) 75 (50.3) 131 (81.8) 78 (59.5)
Acinetobacter species 43 40 (93.0) 22 (55.0) 39 (90.7) 17 (43.6) 31 (72.1) 17 (54.8)
Pseudomonas species 16 15 (93.7) 6 (40.0) - - 11 (68.7) 7 (63.6)
Others 1
Gram positives 811 762 (93.9) 276 (36.3)b 770 (94.9) 144 (18.7)a 723 (89.1) 468 (64.7)c C > B < A; p = 0.001
Enterococcus species 36 29 (80.5) 8 (27.5) 34 (94.4) 9 (26.4) - -
Staphylococcus
aureus
159 143 (89.9) 64 (44.7) 151 (94.9) 22 (14.6) 142 (89.3) 82 (57.7)
CoNS 549 539 (98.2) 183 (34.0)b 540 (98.3) 97 (17.9)a 531 (96.7) 366 (68.9)c C > B < A; p = 0.001
Streptococcus species 58 51 (97.9) 21 (41.0) 45 (77.5) 16 (35.5) 50 (86.2) 20 (40.0)
Others 9
Total 1031 962 (93.3) a348 (36.2)
b 958 (92.9) a236 (24.6)
a 896 (86.9) a570 (63.6)
c C > B < A; p = 0.001
Total excluding CoNS 482 423 (87.8) a165 (39.0)
b 418 (86.7) b139 (33.2)
a 365 (75.7) b204 (55.8)
c C > B < A; p = 0.001
Polymicrobial infections 25 16 (64.0) 3 (18.7) 14 (56.0) 3 (21.4) 16 (64.0) 6 (37.7) C = B = A; p = 0.431
2 organisms 22 14 (63.6) 2 (14.2) 12 (54.5) 2 (16.7) 15 (68.2) 5 (33.3)
3 organisms 3 2 (66.7) 1 (50.0) 2 (66.7) 1 (50.0) 1 (33.3) 1 (100.0)
Based on in-vitro susceptibility. Data on isolates with insufficient numbers (n ≤ 5) not shown. For polymicrobial infections, all isolates were susceptible to at least one of the treatment antibiotics
A, Ampicillin plus Gentamicin; B, Ampicillin plus cefotaxime; C, Cloxacillin plus gentamicin; CoNS, Coagulase negative Staphylococcus species. Other Gram-negatives included Neisseria species (n = 1), Stenophromonas
species (n = 1) and Moraxella species (n = 1). Other Gram-positives included Micrococcus species (n = 5), and Sterptomyces species (n = 4)
Differing superscripts across row denotes differences in the proportion of susceptible isolates to antimicrobial regimen. Differences in proportions computed by Chi square with Marascuilo’s Post Hoc Multiple
proportion comparisons at p-value <0.05. Differing subscripts within a column denotes differences in the proportion of susceptible isolates to antimicrobial regimen
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The incidence of Ceph-R Ent. and MDR Act. were sig-
nificantly higher among LOS than in EOS. Meanwhile,
VRE, MRSA, PRS and MDR Ps. were equally prevalent
in LOS and EOS. Overall 53 % (n = 917/1763) of the
total isolates exhibited MDR, accounting for about 50 %
(n = 886/1763) of total bloodstream infections. Gram
negative bacteria had more MDRs (71.7 %; n = 236/329)
than GPB (47.9 %; n = 681/1421) (p-value =0.001). The
MDRs were less prevalent (p-value <0.001) in EOS
(37.3 %, n = 331/886) compared to LOS (62.4 %, n = 555/
886). The yearly incidence of all MDRs remained rela-
tively stable from 2010 through 2014 for EOS (Chi-square
for trend, p-value = 0.284) and LOS (Chi-square for linear
trend, p-value = 0.531).
Discussion
The rise in antibiotic resistance worldwide means that
empirical therapy guided by local susceptibility is critical
for improved therapeutic outcomes. In this study about
a quarter of all neonatal blood cultures in our institution
over a four year period were positive. We found a high
prevalence of Gram-positive organisms which contrasts
with previous findings in our hospital [5] and elsewhere
[14, 15] where Gram-negative bacteria were the predom-
inant organisms isolated. Coagulase negative Staphylo-
coccus was the predominant organism identified in our
study. The role played by CoNS in neonatal bloodstream
infections is however not clear, as isolation from a single
blood culture may represent true bacteraemia or con-
tamination [16, 17]. Coagulase negative Staphylococcus
have been found to play a significant role in bloodstream
infections in neonates with low birth weight and gesta-
tional age [16–18] as well as in those with intravascular
catheters insitu. In this study however, we were unable
to ascertain the percentage of neonates with low birth
weight; although anecdotally there is very low use of
central catheters among neonates at the KBTH. Others
have also suggested that a majority of blood cultures in
neonates are performed in the first few days of life be-
cause of perceived risk factors of sepsis and not for clin-
ical features of sepsis; and this may account for high
rates of contamination with CoNS [19]. Thus it is pos-
sible that the high rate of isolation of CoNS from our
study may point to high contamination rates from skin
flora due to poor skin disinfection techniques. Despite
this, other studies have reported high prevalence of
CoNS among neonatal blood cultures [1, 2, 20].
Members of the Enterobacteriaceae were the common-
est Gram negative organisms, with Citrobacter species,
Enterobacter species and Klebsiella species accounting for
the majority of organisms. This is in accordance with find-
ings from other developing countries [1, 2, 14, 15, 21] as
well as previous reports among neonates in KBTH [5].
The major role played by Enterobacteriaceae in neonatal
sepsis may reflect a high rate of healthcare associated
infections among our neonatal population, with these in-
fections likely to have been transmitted from the environ-
ment by healthcare personnel and parents [4].
This study confirmed findings of low prevalence of
Streptococcus agalactaie as a cause of EOS [5] This is
contrary to findings in developed countries where EOS
is mostly associated with Streptococcus agalactiae [3, 6].
However, similar findings of low prevalence have been
made in other developing countries [2, 14, 15, 20, 21]. The
prevalence of Streptococcus agalactiae in this study was
low (0.68 %), despite a previous study showing Streptococ-
cus agalactiae colonization rate of 19 % among pregnant
women [22]. This finding may point to a minimal role
Fig. 1 Antibiotic resistance across study years. CoNS, coagulase negative staphylococci; %, percentage. Resistance of blood culture isolates (with or
without CoNS) to ampicillin/cefotaxime significantly increased over study period. Resistance to ampicillin/gentamicin and cloxacillin/gentamicin
remained relatively unchanged from 2010 through 2013
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played by Streptococcus agalactiae in neonatal sepsis in
our environment.
The overall susceptibility of blood culture isolates (with
and without CoNS) to the antibiotics commonly used
showed low susceptibility levels for the recommended reg-
imens of ampicillin/gentamicin and ampicillin/cefotaxime
[9, 10]. Cloxacillin/gentamicin had improved coverage
over the national treatment guidelines, and remained
the most active antibiotic combination despite a moder-
ate coverage of <65.6 % for all bacterial isolates (with or
without CoNS). This observation is in agreement with
previous studies in Ghana and at Korle-Bu teaching Hos-
pital, that found high resistance to ampicillin, gentamicin
and cefotaxime among Gram negative isolates [23–25]. It
is also the experience in KBTH that resistance to many
routinely used antibiotics is high; and the prevalence is ris-
ing [25]. The pattern of resistance further mirrors findings
from other developing countries were ampicillin and gen-
tamicin have been found not to be very effective [4]. This
suggests that current national antibiotic guidelines for
neonatal sepsis may not be appropriate for management
of neonatal infections in our study setting. Our results
identified a pattern of resistance across neonatal age for
all antibiotic combinations. When data excluded CoNS,
we observed a decline in resistance for bacteria causing
BSI in neonates aged <3 days for each of the antibiotic
combinations. The rate in decrease of resistance was
highest for cloxacillin/gentamicin. When data included
CoNS, our results identified an age (9 days) beyond
which antibiotic resistance appear to increase. This rate
Fig. 2 Change in the odds of antibiotic resistance in (i) all bacteria (i) and excluding coagulae negative Staphylococcus species (ii) Models are
linear spline function estimates shown on the logit scale based on the least Akaike’s Information Criterion (Additional file 1: Table S1)
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of increase in resistance was slowest for cloxacillin/gen-
tamicin. Early onset resistance may point to the role
played by resistant organisms of maternal origin, whilst
increasing resistance over time may be indicative of in-
creased role played by healthcare related infections
which is associated with increased chances of antibiotic
resistance [3]. This observation is reflected in our find-
ing that GNB (which were more often MDRs; and are
frequently associated with hospital flora) were domin-
ant in LOS.
Also the study showed high levels of cefotaxime resist-
ant Enterobacteriaceae which is a possible marker for ex-
tended spectrum beta lactamase (ESBL) production.
However, data on ESBLs were not available for the study
isolates. There was also high level of multi-drug resistant
Acinetobacter species, but low levels of VRE and MRSA,
and absence of carbapenem resistant Enterobacteriaceae.
The KBTH has a higher prevalence (>40 %) of infections
caused by ESBL-producers [25, 26] compared to MRSA
(<10 %) [27]. High rates of ESBL-producers have been re-
ported in community-acquired and neonatal bloodstream
infections elsewhere in Ghana [28]. It is also anecdotal ex-
perience that CRE are encountered more often than VRE,
but there are no published reports to document this evi-
dence. This study shows that continuous surveillance of
bloodstream infections among the neonatal populations in
Ghana is needed to inform management strategies and
policy which will contribute to the reduction of neonatal
mortality from sepsis. The study had some limitations.
Our study was retrospective thus affected by missing data
including diagnosis of patients at time of sampling. Also,
it was not possible to compare in vitro susceptibility test-
ing of recommended antibiotic combinations with in vivo
clinical efficacy.
Conclusion
From our study we observed a blood culture positivity rate
of 21.9 % among neonates with most infections being of
late onset. Coagulase negative Staphylococcus species were
the commonly isolated organism in both early and late on-
set bacteraemia although their exact pathogenic role could
not be determined. Whilst members of the Enterobacteri-
aceae (Citrobacter species, Enterobacter species, Klebsiella
species) represented the commonest Gram negative or-
ganisms isolated. There was very high resistance to ampi-
cillin/gentamicin and ampicillin/cefotaxime combinations
among the isolated organism whilst relatively high suscep-
tibility was observed to cloxacillin/gentamicin combin-
ation. Continuous surveillance of neonatal bloodstream
infections is required to guide hospital and national anti-
biotic treatment guidelines to improve morbidity and
mortality associated with neonatal bloodstream infections.
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